Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

8.8K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.8K
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

8.9K
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
8.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Regulation of the Unfolded Protein Response01:31

Regulation of the Unfolded Protein Response

3.1K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
3.1K
Autophagic Cell Death01:18

Autophagic Cell Death

4.7K
Christian de Duve discovered “autophagy,” a process in which cellular components are engulfed by membrane-bound organelles called autophagosomes. The autophagosomes then fuse with lysosomes to digest the enclosed contents. Autophagy is generally activated in cells to prevent cell death. However, cell death is triggered when the damage is beyond repair.
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
4.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enrichment of CD103<sup>+</sup> CD4<sup>+</sup> T cells in bone metastases compared to non-malignant controls.

Immunology letters·2026
Same author

Using a novel panel of drug-resistant triple-negative breast cancer cell lines to identify candidate therapeutic targets and biomarkers.

Cancer letters·2025
Same author

Expression of the TIGIT axis and the CD39/CD73 purinergic pathway in bone metastasis-derived immune cells.

Cancer immunology, immunotherapy : CII·2025
Same author

Targeting the AKT/mTOR pathway attenuates the metastatic potential of colorectal carcinoma circulating tumor cells in a murine xenotransplantation model.

Molecular oncology·2025
Same author

Murine Regulatory CD4<sup>+</sup> T Cells Are Increased in Leukemic Spleens and Show High Co-Expression of Co-Regulatory Molecules CD39, CD73, PD1, and TIGIT.

International journal of molecular sciences·2024
Same author

Expression of CD39 is associated with T cell exhaustion in ovarian cancer and its blockade reverts T cell dysfunction.

Oncoimmunology·2024

Related Experiment Video

Updated: Feb 20, 2026

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

7.8K

RUNX1 Upregulation by Cytotoxic Drugs Promotes Apoptosis.

Daniel Speidel1, Jasmin Wellbrock2, Melissa Abas3

  • 1Children's Medical Research Institute, The University of Sydney, Westmead, New South Wales, Australia. dspeidellab@gmail.com.

Cancer Research
|October 22, 2017
PubMed
Summary

RUNX1 upregulation by chemotherapy enhances DNA damage response and cell death in leukemia. Mutations in RUNX1

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.6K
Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
09:16

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

8.1K

Related Experiment Videos

Last Updated: Feb 20, 2026

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

7.8K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.6K
Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
09:16

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

8.1K

Area of Science:

  • Hematology
  • Molecular Biology
  • Cancer Research

Background:

  • Mutations in the RUNX1 gene are linked to poor prognosis and chemotherapy resistance in hematologic malignancies like acute myeloid leukemia (AML).
  • The precise mechanisms by which RUNX1 influences therapeutic outcomes in these cancers are not fully understood.

Purpose of the Study:

  • To investigate the direct role of RUNX1 in the response of hematopoietic cells to cytotoxic chemotherapy agents.
  • To elucidate the functional significance of the RUNX1 runt homology domain (RHD) in mediating cellular responses to DNA damage and chemotherapeutic agents.

Main Methods:

  • Investigated RUNX1 expression in C57BL/6 mice and hematopoietic cell lines treated with cytotoxic agents.
  • Analyzed RUNX1 upregulation in primary human AML cells after cytarabine treatment.
  • Examined the effects of RUNX1 overexpression on cell proliferation, apoptosis, and DNA damage response.
  • Assessed the functional impact of RHD-defective RUNX1 mutants on cellular sensitivity to ionizing radiation.

Main Results:

  • Cytotoxic agents upregulated RUNX1 posttranscriptionally in vivo and in vitro, including in primary AML cells.
  • Overexpression of RUNX1 restricted proliferation, promoted apoptosis, and augmented DNA damage response.
  • RUNX1's anti-proliferative and pro-apoptotic functions required an intact RHD.
  • RHD-defective RUNX1 mutants exhibited reduced or absent anti-proliferative/apoptotic activity and could confer resistance to ionizing radiation.

Conclusions:

  • RUNX1 plays a novel role in mediating hematopoietic cell responses to cytotoxic agents, influencing proliferation, apoptosis, and DNA damage.
  • RUNX1's function in this context is dependent on its RHD, explaining how mutations in this domain contribute to chemoresistance.
  • Targeting RUNX1 pharmacologically presents a potential therapeutic strategy for hematologic malignancies.